Earnings Neutral 5

Evolent and Standard BioTools Signal Shift to Efficiency in 2025 Results

· 3 min read · Verified by 2 sources · By SaaS Intelligence Brief Editorial
Share

Key Takeaways

  • Evolent and Standard BioTools reported strong 2025 revenue growth, with Evolent crossing the $2.6 billion threshold and Standard BioTools achieving its first positive adjusted EBITDA quarter.
  • Both companies are now pivoting toward margin expansion and operational discipline as they enter the 2026 fiscal year.

Mentioned

Evolent company EVH Standard BioTools company LAB CyTOF technology

Key Intelligence

Key Facts

  1. 1Evolent reported full-year 2025 revenue of $2.6 billion, a 31.6% year-over-year increase.
  2. 2Standard BioTools achieved its first positive Adjusted EBITDA quarter in Q4 2025, totaling $4.2 million.
  3. 3Evolent's 2026 revenue guidance is set between $2.8 billion and $2.9 billion.
  4. 4Standard BioTools reported Q4 revenue of $51.2 million, up 14% from the prior year.
  5. 5Evolent posted a full-year GAAP net loss of $77.1 million despite strong operational growth.
  6. 6Standard BioTools projects 2026 revenue to reach between $215 million and $225 million.
Metric (FY 2025)
Total Revenue $2.6B $195.4M
Revenue Growth (YoY) 31.6% 10.0%
Adj. EBITDA $225.0M ($18.5M)
GAAP Net Loss ($77.1M) ($68.2M)
2026 Sector Outlook

Analysis

The fourth-quarter and full-year 2025 financial results from Evolent and Standard BioTools underscore a critical maturation phase for specialized SaaS and life sciences technology providers. As the broader cloud market moves away from a 'growth at any cost' mentality, these two entities are demonstrating how scale and operational efficiency can coexist. Evolent, a leader in value-based care solutions, reported a significant revenue surge, while Standard BioTools reached a long-awaited profitability milestone on an adjusted basis, signaling that its restructuring efforts are beginning to yield tangible results.

Evolent’s performance in 2025 was defined by its ability to scale its Specialty Care and Performance Suite offerings. The company reported full-year revenue of approximately $2.6 billion, representing a 31.6% increase over the previous year. This growth is largely attributed to the increasing adoption of its clinical platform by major health plans and providers seeking to manage complex conditions like oncology and cardiology more effectively. Despite the top-line success, the company remains in a net loss position on a GAAP basis, reporting a $77.1 million loss for the year. However, its Adjusted EBITDA of $225 million provides a clearer picture of the underlying cash-generative nature of its SaaS-driven model once non-recurring integration and stock-based compensation costs are excluded.

Evolent has guided for 2026 revenue between $2.8 billion and $2.9 billion, suggesting that while growth will remain in the double digits, the pace is moderating as the company focuses on integrating its recent acquisitions and expanding its margins.

Standard BioTools, operating at the intersection of life sciences and data technology, reported Q4 revenue of $51.2 million, a 14% year-over-year increase. The most significant takeaway from their report was the achievement of $4.2 million in positive Adjusted EBITDA for the quarter—the first such occurrence in the company’s recent history. This milestone is a direct result of the company's strategic focus on its mass cytometry (CyTOF) and microfluidics platforms, which are increasingly viewed as essential infrastructure for high-dimensional proteomics research. By streamlining its cost structure and focusing on high-margin recurring revenue from consumables and software subscriptions, Standard BioTools is positioning itself as a leaner, more sustainable player in the life sciences cloud ecosystem.

What to Watch

Comparing the two, Evolent is leveraging its massive scale to dominate the healthcare services market, while Standard BioTools is proving the viability of a specialized technology niche. Both companies face a similar challenge in 2026: navigating a high-interest-rate environment that demands GAAP profitability. Evolent has guided for 2026 revenue between $2.8 billion and $2.9 billion, suggesting that while growth will remain in the double digits, the pace is moderating as the company focuses on integrating its recent acquisitions and expanding its margins. Standard BioTools, meanwhile, is forecasting revenue in the range of $215 million to $225 million, reflecting a cautious but optimistic outlook for the research and diagnostics markets.

For investors and industry observers, these results indicate that the 'SaaS-ification' of healthcare and life sciences is entering a second act. The initial phase was defined by rapid platform adoption and market land-grabs; this new phase is defined by the rigorous optimization of those platforms to deliver both clinical outcomes and financial returns. As Evolent and Standard BioTools move into 2026, their ability to maintain technological leadership while achieving bottom-line stability will be the primary barometer for their success in an increasingly disciplined market.

Related Stories

Earnings

Adobe SaaS Revenue Reaches $6.62B as AI ARR Doubles QoQ

Adobe’s Q2 FY26 SaaS metrics defy disruption fears: total revenue grew 13% to $6.62B while AI-first ARR surged 200% YoY. With full-year guidance raised to $26.55B and 45%+ margins, the subscription model proves AI is additive, not destructive.

Earnings

Navan (NAVN) Q4 2026: AI-Driven Expense Growth and Margin Expansion

Navan reported a standout Q4 2026, driven by a 48% surge in its high-margin expense management software and the successful deployment of its AI assistant, Ava. The company achieved its third consecutive quarter of positive free cash flow, signaling a successful transition from a travel-heavy model to a diversified SaaS and fintech powerhouse.

Earnings

Cloud-Enabled Platforms and 5G Connectivity Drive Q4 Commercial Inflections

A diverse cohort of technology and platform providers reported strong Q4 2025 results, signaling a shift from R&D-heavy cycles to commercial scalability. Key players in fintech, e-commerce, and 5G semiconductors demonstrated significant operating leverage as AI-driven automation and next-generation connectivity reached market maturity.

Earnings

Braze Q4 2026: AI Orchestration and Enterprise Gains Drive SaaS Resilience

Braze reported robust Q4 2026 financial results, underscored by the successful scaling of its AI-driven 'Braze Sage' suite and continued displacement of legacy marketing clouds. The company demonstrated a clear path toward sustained non-GAAP profitability while maintaining double-digit revenue growth in a competitive enterprise landscape.

How we covered this story

Every story in our saas coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the saas space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled saas-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.